Healthcare
Mainz Biomed N.V.(QUCY)
Live Price
Offline$1.76
-7.37% today
1Y Change
+39.57%
Window
Jun 23, 2025 โ Jun 16, 2026
- Market Cap
- $10.00M
- Revenue Growth
- -0.2%
- EPS Growth
- +65.5%
- Dividend Yield
- 0.0%
Coverage: 247 bars ยท Jun 23, 2025 โ Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Mainz Biomed N.V. (QUCY) is a Healthcare stock with a market cap of $10.00M and listed on NASDAQ. The stock last traded around $1.76 and up 39.6% across the available one-year price window (Jun 23, 2025 โ Jun 16, 2026). Baseline metrics include revenue growth of -0.2%, EPS growth of +65.5%, a dividend yield of 0.0%. What stands out right now is revenue -0.2%, EPS +65.5%, free cash flow +27.2% with operating margin -2091.2% and ROIC -192.9%. Valuation sits in the middle of the pack at price/sales 5.6. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines QUCY price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-0.2% vs +7.6% peer median
Operating Margin
Below sector median
-2091.2% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Apr 14, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -0.2% and EPS is at +65.5%, with operating margin around -2091.2%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 2 reported quarters, the stock averaged +6.0% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Apr 14, 2026 | โ | -9.9% | -13.5% | -46.8% |
2026 Apr 7, 2026 | โ | +5.4% | +25.4% | -24.8% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
QUCY
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
QUCY Max Drawdown
-84.84%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for QUCY and SPY.
Company Overview
Mainz Biomed N.V.
NASDAQ Global Market
Mainz Biomed NV is a molecular genetics cancer diagnostic company. The firm is engaged in the developing of market-ready molecular genetic diagnostic solutions for life-threatening conditions. It is involved in the commercializing of its product portfolio in Europe, the United States, and the rest of world. The company was founded on March 08, 2021 and is headquartered in Mainz, Germany.
- Leadership
- Guido Baechler
- IPO Date
- Nov 5, 2021
- Employees
- 26
- Street Address
- Robert Koch Strasse 50
- Mailing
- Mainz, 55129
- Region
- Mainz, DE
- Reporting Currency
- USD
- Investor Line
- 49 6131 554 2860
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 5.6
- Price/Book
- 0.1
Growth
- Revenue
- -0.2%
- EPS
- +65.5%
- Free Cash Flow
- +27.2%
Profitability
- Gross Margin
- 64.3%
- Operating Margin
- -2091.2%
- Net Margin
- -2421.8%
- ROE
- -465.8%
- ROIC
- -192.9%
Balance Sheet
- Debt/Equity
- 0.54
- Current Ratio
- 1.32
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.